当前位置:
X-MOL 学术
›
Cancer Cell
›
论文详情
Our official English website, www.x-mol.net, welcomes your feedback! (Note: you will need to create a separate account there.)
The promise and peril of KRAS G12C inhibitors
Cancer Cell ( IF 50.3 ) Pub Date : 2021-08-09 , DOI: 10.1016/j.ccell.2021.07.011 Amanda R Moore 1 , Shiva Malek 1
中文翻译:
KRAS G12C抑制剂的前景和危险
更新日期:2021-08-09
Cancer Cell ( IF 50.3 ) Pub Date : 2021-08-09 , DOI: 10.1016/j.ccell.2021.07.011 Amanda R Moore 1 , Shiva Malek 1
Affiliation
RAS mutant tumors have been largely refractory to therapies until now. Recent findings published in the New England Journal of Medicine show that sotorasib provides clinical benefit for KRAS p.G12C-mutated non-small-cell lung cancer (NSCLC) and provide mechanistic insights into acquired resistance to KRASG12C-specific inhibition.
中文翻译:
KRAS G12C抑制剂的前景和危险
迄今为止,RAS突变肿瘤在很大程度上对治疗无效。最近发表在《新英格兰医学杂志》上的研究结果表明,索托拉西为KRAS p.G12C 突变的非小细胞肺癌 (NSCLC) 提供了临床益处,并提供了对 KRAS G12C特异性抑制获得性耐药的机制见解。